These results suggest that miR-106b may be a driver of bone resorption via targeting multiple genes including RANKL, and may provide a new possible approach to the diagnosis and treatment of GCT and other diseases associated with bone destruction, such as postmenopausal osteoporosis and bone metastasis. The gene discussed is TNFSF11; the disease is metastasis.